BRISTOL-MYERS SQUIBB COMPANY Deferred Income Tax Assets, Net
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Deferred Income Tax Assets, Net of $5.36 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredIncomeTaxAssetsNet · last filed 2026-07-30
- 2026-06-30: Deferred Income Tax Assets, Net $5.36B.
- 2026-03-31: Deferred Income Tax Assets, Net $5.18B.
- 2025-12-31: Deferred Income Tax Assets, Net $5.38B.
- 2025-09-30: Deferred Income Tax Assets, Net $4.96B.
| Period end | Deferred Income Tax Assets, Net |
|---|---|
| 2026-06-30 | $5.36B 10-Q · filed 2026-07-30 |
| 2026-03-31 | $5.18B 10-Q · filed 2026-04-30 |
| 2025-12-31 | $5.38B 10-Q · filed 2026-07-30 |
| 2025-09-30 | $4.96B 10-Q · filed 2025-10-30 |
| 2025-06-30 | $4.65B 10-Q · filed 2025-07-31 |
| 2025-03-31 | $4.00B 10-Q · filed 2025-04-24 |
| 2024-12-31 | $4.24B 10-K · filed 2026-02-11 |
| 2024-09-30 | $3.61B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $3.32B 10-Q · filed 2024-07-26 |
| 2024-03-31 | $2.72B 10-Q · filed 2024-04-25 |
| 2023-12-31 | $2.77B 10-K · filed 2025-02-12 |
| 2023-09-30 | $1.51B 10-Q · filed 2023-10-26 |
| 2023-06-30 | $1.57B 10-Q · filed 2023-07-27 |
| 2023-03-31 | $1.32B 10-Q · filed 2023-04-27 |
| 2022-12-31 | $1.34B 10-K · filed 2024-02-13 |
| 2022-09-30 | $1.33B 10-Q · filed 2022-10-26 |
| 2022-06-30 | $1.34B 10-Q · filed 2022-07-27 |
| 2022-03-31 | $1.42B 10-Q · filed 2022-04-29 |
| 2021-12-31 | $1.44B 10-K · filed 2023-02-14 |
| 2021-09-30 | $684.00M 10-Q · filed 2021-10-27 |
| 2021-06-30 | $650.00M 10-Q · filed 2021-07-28 |
| 2021-03-31 | $793.00M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $1.16B 10-K · filed 2022-02-09 |
| 2020-09-30 | $913.00M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $1.09B 10-Q · filed 2020-08-06 |
| 2020-03-31 | $605.00M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $510.00M 10-K · filed 2021-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |